Progenics Pharmaceuticals Announces Key Strategic Hire

Progenics Pharmaceuticals Announces Key Strategic Hire

TARRYTOWN, N.Y., July 1, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) today announced the appointment of Hagop Youssoufian, MD,
as Executive Vice President, Research & Development. Dr. Youssoufian will
oversee the Company's global research and development efforts and will be
instrumental in driving the strategic trajectory of the Company's
developmental stage oncology assets.

"I am pleased to have Dr. Youssoufian join our experienced team at Progenics
as we move three late stage clinical oncology programs forward towards
commercialization," said Mark Baker, CEO of Progenics."Hagop brings to
Progenics a wealth of healthcare industry experience and knowledge that will
support and further our mission to become a pre-eminent oncology company."

Prior to joining Progenics Dr. Youssoufian held increasingly senior roles with
global responsibilities in the pharmaceutical industry.Most recently, he was
President, Research & Development and Chief Medical Officer at Ziopharm
Oncology.Prior to joining Ziopharm, Dr. Youssoufian worked at Imclone
Systems, Sanofi Aventis and Bristol-Myers Squibb.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for
oncology, with a pipeline that includes several product candidates in
late-stage clinical development.Progenics first-in-class PSMA targeted
technology platform includes an antibody drug conjugate therapeutic and a
small molecule targeted imaging agent, both in Phase II clinical trials. Its
late stage ultra-orphan drug candidate, Azedra, was filed under an SPA which
may facilitate fast-tracked approval and commercialization.Progenics' first
commercial product, Relistor^® (methylnaltrexone bromide) for opioid-induced
constipation, is partnered with and marketed by Salix Pharmaceuticals,
Inc.Ono Pharmaceutical Co., is developing Relistor^® in Japan. For additional
information, please visit

This press release may contain projections and other forward-looking
statements regarding future events. Such statements are predictions only, and
are subject to risks and uncertainties that could cause actual events or
results to differ materially. These risks and uncertainties include, among
others, the cost, timing and results of clinical trials and other development
activities; the unpredictability of the duration and results of regulatory
review of New Drug Applications and Investigational NDAs; market acceptance
for approved products; generic and other competition; the possible impairment
of, inability to obtain and costs of obtaining intellectual property rights;
and possible safety or efficacy concerns, general business, financial and
accounting matters, litigation and other risks. More information concerning
Progenics and such risks and uncertainties is available on its website, and in
its press releases and reports it files with the U.S. Securities and Exchange
Commission. Progenics is providing the information in this press release as of
its date and does not undertake any obligation to update or revise it, whether
as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available
in press releases or other public announcements and public filings made after
this release.


CONTACT: Kathleen Fredriksen
         Director of Corporate Development
         (914) 789-2871

company logo
Press spacebar to pause and continue. Press esc to stop.